EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CTLA4 , SH2B3 , and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients

Julie Vandewalle iD, Aster K Desouter iD, Bart J Van der Auwera iD, Sylvie Tenoutasse iD, Pieter Gillard iD, Christophe De Block iD, Bart Keymeulen iD, Frans K Gorus iD, Mark Van de Casteele iD, Belgian Diabetes Registry

Clinical and Experimental Immunology · 2023

DOI: 10.1093/cei/uxad002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von Julie Vandewalle und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes Pathology and Therapy, Vrije Universiteit Brussel (VUB), Brussels, Belgium. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vrije Universiteit Brussel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The HLA region is the major genetic risk determinant of Type 1 diabetes. How non-HLA loci contribute to the genetic risk is incompletely understood, but there are indications that at least some impact progression of asymptomatic autoimmunity. We examined whether SNPs in 7 susceptibility loci (INS, SH2B3, PTPN2, PTPN22, CTLA4, CLEC16A, and IL2RA) could improve prediction of the progression from single to multiple autoantibody positivity, and from there on to diagnosis. SNPs were genotyped in persistently autoantibody positive relatives by allelic discrimination qPCR and disease progression was studied by multivariate Cox regression analysis. In our cohort, only the CTLA4 GA genotype (rs3087243, P = 0.002) and the CLEC16A AA genotype (rs12708716, P = 0.021) were associated with accelerated progression from single to multiple autoantibody positivity, but their effects were restricted to presence of HLA-DQ2/DQ8, and IAA as first autoantibody, respectively. The interaction of CTLA4 and HLA-DQ2/DQ8 overruled the effect of DQ2/DQ8 alone. The HLA-DQ2/DQ8-mediated risk of progression to multiple autoantibodies nearly entirely depended on heterozygosity for CTLA4. The SH2B3 TT genotype (rs3184504) was protective for HLA-DQ8 positive subjects (P = 0.003). At the stage of multiple autoantibodies, only the CTLA4 GA genotype was a minor independent risk factor for progression towards clinical diabetes (P = 0.034). Our study shows that non-HLA polymorphisms impact progression of islet autoimmunity in a subgroup-, stage- and SNP-specific way, suggesting distinct mechanisms. If confirmed, these findings may help refine risk assessment, follow-up, and prevention trials in risk groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1HumansAutoantibodiesAutoimmunityCTLA-4 AntigenGenetic Predisposition to DiseaseGenotypeLectins, C-TypeMonosaccharide Transport ProteinsPolymorphism, Single NucleotideProtein Tyrosine Phosphatase, Non-Receptor Type 22Adaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

CLEC16ACTLA4SH2B3Type 1 diabetesautoimmunityprediction

Substanzen

AutoantibodiesCTLA-4 AntigenLectins, C-TypeMonosaccharide Transport ProteinsProtein Tyrosine Phosphatase, Non-Receptor Type 22CLEC16A protein, humanCTLA4 protein, humanPTPN22 protein, humanSH2B3 protein, humanAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Department of Diabetes Pathology and Therapy, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Department of Diabetology and Endocrinology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Department of Diabetology, Hôpital Universitaire des Enfants Reine Fabiola, HUDERF, Université Libre De Bruxelles, Brussels, Belgium.
  • Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Endocrinology, Diabetology and Metabolism, Universitair Ziekenhuis Antwerpen, Edegem, Belgium.

ORCID-Profile: Julie Vandewalle, Aster K Desouter, Bart J Van der Auwera, Sylvie Tenoutasse, Pieter Gillard, Christophe De Block, Bart Keymeulen, Frans K Gorus, Mark Van de Casteele

Förderung

  • Vrije Universiteit Brussel

Zitieren

APA

Vandewalle, J., Desouter, A. K., Van der Auwera, B. J., Tenoutasse, S., Gillard, P., De Block, C., Keymeulen, B., Gorus, F. K., Van de Casteele, M., & Belgian Diabetes Registry (2023). CTLA4 , SH2B3 , and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad002

Vancouver

Vandewalle J, Desouter AK, Van der Auwera BJ, Tenoutasse S, Gillard P, De Block C, et al. CTLA4 , SH2B3 , and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxad002

BibTeX
@article{Vandewalle2023,
  author = {Vandewalle, Julie and Desouter, Aster K and Van der Auwera, Bart J and Tenoutasse, Sylvie and Gillard, Pieter and De Block, Christophe and Keymeulen, Bart and Gorus, Frans K and Van de Casteele, Mark and Belgian Diabetes Registry, Belgian Diabetes Registry},
  title = {CTLA4 , SH2B3 , and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients},
  journal = {Clinical and Experimental Immunology},
  year = {2023},
  doi = {10.1093/cei/uxad002}
}
Kostenlos starten →